Concepedia

Robert E. Bellet

RE

Statistics

Publications

22

Citations

1.6K

H-Index

17

Active since

1972

Affiliations

Fox Chase Cancer Center(Current)

Temple University

Jefferson College

The University of Texas at San Antonio Health Science Center

Thomas Jefferson University Hospital

Robert E. Bellet is an author at Fox Chase Cancer Center specializing in medicine, oncology, and pharmacology.

Publications per year

1972–2008

22

Publications

22

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

Vicente Valero, Frankie A. Holmes, R S Walters et al. · Journal of Clinical Oncology · 1995 · 388 citations

, , +17

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

P. Ravdin, Howard A. Burris, Gary Cook et al. · Journal of Clinical Oncology · 1995 · 319 citations

, , +16

Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials

Edward F. McCiay, Michael J. Mastrangelo, David Berd et al. · International Journal of Cancer · 1992 · 137 citations

, , +12

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

Edward F. McClay, Michael J. Mastrangelo, John D. Sprandio et al. · Cancer · 1989 · 109 citations · Full text

, , +16

Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.

Edward F. McClay, Michael J. Mastrangelo, Robert E. Bellet et al. · PubMed · 1987 · 97 citations

, , +15

1–5 of 22